1. ADENA 1: Data on File. SDZ ENA 713 in mild to moderate senile dementia of the Alzheimer’s type. Study report IND 35-774. Summary of the human pharmacokinetics and bioavailability of ENA 713. Novartis Pharmaceuticals Corporation
2. ADENA 2: Data on File. Summary of product characteristics. January 1998. Novartis Pharmaceuticals Corporation
3. ADENA 3: Data on File. Draft labeling. April 1997, NDA 20-823. Novartis Pharmaceuticals Corporation
4. ADENA 4: Data on File. Integrated summary of effectiveness. 15 April 1997. Novartis Pharmaceuticals Corporation
5. ADENA 5: Anand R, Gharabawi G. The ADENA programme: International coordinated phase III development of a second generation acetylcholinesterase inhibitor (SDZ ENA-713). Poster presentation